Cellectar Biosciences Net Income Over Time
| CLRB Stock | USD 3.22 0.02 0.62% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Cellectar Biosciences Performance and Cellectar Biosciences Correlation. Cellectar | Build AI portfolio with Cellectar Stock |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cellectar Biosciences. Projected growth potential of Cellectar fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Cellectar Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Cellectar Biosciences requires distinguishing between market price and book value, where the latter reflects Cellectar's accounting equity. The concept of intrinsic value—what Cellectar Biosciences' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Cellectar Biosciences' price substantially above or below its fundamental value.
It's important to distinguish between Cellectar Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cellectar Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Cellectar Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Cellectar Biosciences and related stocks such as AEON Biopharma, Bolt Biotherapeutics, and Cingulate Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AEON | 172.9 M | 172.9 M | 172.9 M | 172.9 M | 172.9 M | 172.9 M | 172.9 M | 172.9 M | 172.9 M | 172.9 M | (32.9 M) | (55.6 M) | (52.6 M) | (384.6 M) | 42 M | 37.8 M | 39.7 M |
| BOLT | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (30.5 M) | (60.7 M) | (98.6 M) | (88.1 M) | (69.2 M) | (63.1 M) | (56.8 M) | (59.6 M) |
| CING | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (7.2 M) | (20.7 M) | (17.9 M) | (23.5 M) | (15.5 M) | (14 M) | (14.7 M) |
| SNSE | (13 M) | (13 M) | (13 M) | (13 M) | (13 M) | (13 M) | (13 M) | (13 M) | (13 M) | (16.7 M) | (20.1 M) | (36.8 M) | (48.8 M) | (34.1 M) | (30.2 M) | (27.1 M) | (28.5 M) |
| LYRA | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (16.3 M) | (22.1 M) | (42.4 M) | (55.3 M) | (62.7 M) | (93.4 M) | (84.1 M) | (79.9 M) |
| IMNN | (1.9 M) | (23.2 M) | (26.6 M) | (8.3 M) | (25.5 M) | (22.5 M) | (22.1 M) | (20.4 M) | (11.9 M) | (16.9 M) | (21.5 M) | (20.8 M) | (35.9 M) | (19.5 M) | (18.6 M) | (16.8 M) | (17.6 M) |
| MRKR | (1.1 M) | (2 M) | (5.9 M) | (5.5 M) | (30.9 M) | (34.1 M) | (2.5 M) | (11 M) | (148 M) | (21.4 M) | (28.7 M) | (41.9 M) | (29.9 M) | (8.2 M) | (10.7 M) | (9.7 M) | (10.1 M) |
| EVGN | 645 K | 645 K | (2.5 M) | (8.9 M) | (14.5 M) | (17.2 M) | (19.6 M) | (20.8 M) | (20.8 M) | (18.1 M) | (23.4 M) | (27.8 M) | (26.6 M) | (23.9 M) | (16.5 M) | (14.8 M) | (15.6 M) |
| RNAZ | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (607.2 K) | (2.3 M) | (6.8 M) | (17.6 M) | (18.5 M) | (16.8 M) | (15.1 M) | (14.3 M) |
| MBIO | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (12.7 M) | (31.3 M) | (30.7 M) | (48.2 M) | (60 M) | (66.4 M) | (77.5 M) | (51.6 M) | (15.8 M) | (14.2 M) | (14.9 M) |
Cellectar Biosciences and related stocks such as AEON Biopharma, Bolt Biotherapeutics, and Cingulate Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Cellectar Biosciences financial statement analysis. It represents the amount of money remaining after all of Cellectar Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Cellectar Biosciences | CLRB |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 100 Campus Drive, |
| Exchange | NASDAQ Exchange |
USD 3.22
Check out Cellectar Biosciences Performance and Cellectar Biosciences Correlation. For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Cellectar Biosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.